Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Primary:
To determine the duration of use of zoledronic acid in improving Bone mineral density in
patients with prostate cancer who are on hormones intermittently.
Secondary Objectives:
To describe the safety and tolerability at this dose and schedule